ATE305787T1 - 3,4-dihydro-(1h)chinazolin-2-on-verbindungen als csbp/p39-kinase-inhibitoren - Google Patents

3,4-dihydro-(1h)chinazolin-2-on-verbindungen als csbp/p39-kinase-inhibitoren

Info

Publication number: ATE305787T1
Authority: AT; Austria
Prior art keywords: csbp; kinase inhibitors; compounds; chinazoline; dihydro
Prior art date: 1999-11-23

Application number

AT00980576T

Other languages

English (en)

Inventor

Jerry L Adams

Michael J Bower

Jeffrey Charles Boehm

Don E Griswold

David C Underwood

Original Assignee

Smithkline Beecham Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-11-23

Filing date

2000-11-21

Publication date

2005-10-15

2000-11-21 Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp

2005-10-15 Application granted granted Critical

2005-10-15 Publication of ATE305787T1 publication Critical patent/ATE305787T1/de

Links

102100023482 Mitogen-activated protein kinase 14 Human genes 0.000 title abstract 3
108010084680 Heterogeneous-Nuclear Ribonucleoprotein K Proteins 0.000 title abstract 2
229940043355 kinase inhibitor Drugs 0.000 title abstract 2
239000003757 phosphotransferase inhibitor Substances 0.000 title abstract 2
150000001875 compounds Chemical class 0.000 title 1
AVRPFRMDMNDIDH-UHFFFAOYSA-N 1h-quinazolin-2-one Chemical class C1=CC=CC2=NC(O)=NC=C21 AVRPFRMDMNDIDH-UHFFFAOYSA-N 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1
238000002560 therapeutic procedure Methods 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
- C07D239/80—Oxygen atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Physical Education & Sports Medicine (AREA)
Pulmonology (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Oncology (AREA)
Immunology (AREA)
Epidemiology (AREA)
Diabetes (AREA)
Dermatology (AREA)
Virology (AREA)
Communicable Diseases (AREA)
Hematology (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Pain & Pain Management (AREA)
Ophthalmology & Optometry (AREA)
Endocrinology (AREA)
Molecular Biology (AREA)
Emergency Medicine (AREA)
Neurology (AREA)
Obesity (AREA)
Biomedical Technology (AREA)
Transplantation (AREA)

AT00980576T 1999-11-23 2000-11-21 3,4-dihydro-(1h)chinazolin-2-on-verbindungen als csbp/p39-kinase-inhibitoren ATE305787T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US16697299P	1999-11-23	1999-11-23
PCT/US2000/031874 WO2001038313A1 (en)	1999-11-23	2000-11-21	3,4-DIHYDRO-(1H)QUINAZOLIN-2-ONE COMPOUNDS AS CSBP/p39 kINASE INHIBITORS

Publications (1)

Publication Number	Publication Date
ATE305787T1 true ATE305787T1 (de)	2005-10-15

Family

ID=22605414

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT00980576T ATE305787T1 (de)	1999-11-23	2000-11-21	3,4-dihydro-(1h)chinazolin-2-on-verbindungen als csbp/p39-kinase-inhibitoren

Country Status (8)

Country	Link
US (1)	US6982270B1 (de)
EP (1)	EP1233950B1 (de)
JP (1)	JP2003528043A (de)
AT (1)	ATE305787T1 (de)
AU (1)	AU1782301A (de)
DE (1)	DE60023025T2 (de)
ES (1)	ES2249309T3 (de)
WO (1)	WO2001038313A1 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6858617B2 (en)	1998-05-26	2005-02-22	Smithkline Beecham Corporation	Substituted imidazole compounds
US6548503B1 (en)	1998-11-04	2003-04-15	Smithkline Beecham Corporation	Pyridin-4-yl or pyrimidin-4-yl substituted pyrazines
DE60023025T2 (de)	1999-11-23	2006-07-13	Smithkline Beecham Corp.	3,4-dihydro-(1h)chinazolin-2-on-verbindungen als csbp/p39-kinase-inhibitoren
ES2230171T3 (es)	1999-11-23	2005-05-01	Smithkline Beecham Corporation	Compuestos 3,4-dihidro-(1h)quinazolin-2-ona como inhibidores de csbp/p38 quinasa.
WO2001037837A1 (en) *	1999-11-23	2001-05-31	Smithkline Beecham Corporation	3,4-DIHYDRO-(1H)-QUINAZOLIN-2-ONES AND THEIR USE AS CSBP/p38 KINASE INHIBITORS
JP2003514900A (ja) *	1999-11-23	2003-04-22	スミスクライン・ビーチャム・コーポレイション	ＣＳＢＰ／ｐ３８キナーゼ阻害剤としての３，４−ジヒドロ−（１Ｈ）−キナゾリン−２−オン化合物
AU2002248269A1 (en) *	2000-10-19	2002-08-12	Smithkline Beecham Corporation	Use of p38 inhibitors for the treatment of inflammation-enhanced cough
AUPR213700A0 (en)	2000-12-18	2001-01-25	Biota Scientific Management Pty Ltd	Antiviral agents
AU2002325026A1 (en) *	2001-09-27	2003-04-07	St. Jude Children's Research Hospital, Inc.	Use of neuraminidase inhibitors to prevent flu associated bacterial infections
AU2003245989A1 (en)	2002-07-09	2004-01-23	Boehringer Ingelheim Pharma Gmbh And Co. Kg	Pharmaceutical compositions of anticholinergics and p38 kinase inhibitors in the treatment of respiratory diseases
WO2004014869A2 (en) *	2002-08-13	2004-02-19	Warner-Lambert Company Llc	5,6-fused 3,4-dihydropyrimidine-2-one derivatives as matrix metalloproteinase inhibitors
US20060035893A1 (en)	2004-08-07	2006-02-16	Boehringer Ingelheim International Gmbh	Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
PE20060777A1 (es)	2004-12-24	2006-10-06	Boehringer Ingelheim Int	Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
WO2006137421A1 (ja) *	2005-06-21	2006-12-28	Kyowa Hakko Kogyo Co., Ltd.	局所投与剤
US20070231298A1 (en) *	2006-03-31	2007-10-04	Cell Genesys, Inc.	Cytokine-expressing cancer immunotherapy combinations
CA2656507C (en) *	2006-07-17	2012-03-20	Amgen Inc.	Quinazoline and pyridopyrimidine derivatives as p38 kinase inhibitors
CA2681420A1 (en) *	2007-03-20	2008-09-25	Cadila Pharmaceuticals Limited	P38 inhibitors
EP1992344A1 (de)	2007-05-18	2008-11-19	Institut Curie	P38 Alpha als therapeutisches Target für Erkrankungen, die mit einer FGFR3- Mutation assoziiert sind
US20190060286A1 (en)	2016-02-29	2019-02-28	University Of Florida Research Foundation, Incorpo	Chemotherapeutic Methods
GB201611712D0 (en)	2016-07-02	2016-08-17	Hvivo Services Ltd	Methods and compounds for the treatment or prevention of severe or persistent influenza
ES2927715T3 (es)	2017-10-05	2022-11-10	Fulcrum Therapeutics Inc	Inhibidores de la quinasa p38 reducen la expresión de dux4 y de los genes que le siguen para el tratamiento de la FSHD
GB201721793D0 (en) *	2017-12-22	2018-02-07	Hvivo Services Ltd	Methods and compunds for the treatment or prevention of hypercytokinemia and severe influenza

Family Cites Families (139)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2833779A (en)	1956-10-29	1958-05-06	American Cyanamid Co	Substituted pyrazoles
US3707475A (en)	1970-11-16	1972-12-26	Pfizer	Antiinflammatory imidazoles
US3940486A (en)	1971-05-10	1976-02-24	Ciba-Geigy Corporation	Imidazole derivatives in the treatment of pain
US3929807A (en)	1971-05-10	1975-12-30	Ciba Geigy Corp	2-Substituted-4(5)-(aryl)-5(4)-(2,3 or -4-pyridyl)-imidazoles
US4058614A (en)	1973-12-04	1977-11-15	Merck & Co., Inc.	Substituted imidazole compounds and therapeutic compositions therewith
US4199592A (en)	1978-08-29	1980-04-22	E. I. Du Pont De Nemours And Company	Antiinflammatory 4,5-diaryl-2-nitroimidazoles
GR75287B (de)	1980-07-25	1984-07-13	Ciba Geigy Ag
WO1983002613A1 (fr)	1981-07-20	1983-08-04	Sallmann, Alfred	Composes oxazoiques a triple substitution
US4503065A (en)	1982-08-03	1985-03-05	E. I. Du Pont De Nemours And Company	Antiinflammatory 4,5-diaryl 1-2-halo imidazoles
JPS60226882A (ja)	1984-04-24	1985-11-12	Nippon Zoki Pharmaceut Co Ltd	新規ピリミドピリミジン誘導体
US4565875A (en)	1984-06-27	1986-01-21	Fmc Corporation	Imidazole plant growth regulators
US4686231A (en)	1985-12-12	1987-08-11	Smithkline Beckman Corporation	Inhibition of 5-lipoxygenase products
IL83467A0 (en)	1986-08-15	1988-01-31	Fujisawa Pharmaceutical Co	Imidazole derivatives,processes for their preparation and pharmaceutical compositions containing the same
EP0533837A4 (en)	1990-06-12	1994-11-17	Smithkline Beecham Corp	Inhibition of 5-lipoxygenase and cyclooxygenase pathway mediated diseases
FR2665898B1 (fr)	1990-08-20	1994-03-11	Sanofi	Derives d'amido-3 pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
IE913473A1 (en)	1990-10-15	1992-04-22	Fujisawa Pharmaceutical Co	Quinazoline derivatives and their preparation
JPH06504779A (ja)	1990-12-13	1994-06-02	スミスクライン・ビーチャム・コーポレイション	新規ｃｓａｉｄｓ
EP0563286A4 (en)	1990-12-13	1995-01-11	Smithkline Beecham Corp	Novel csaids
WO1992012154A1 (en)	1990-12-31	1992-07-23	Fujisawa Pharmaceutical Co., Ltd.	Imidazotriazine derivatives
GB9816837D0 (en)	1998-08-04	1998-09-30	Zeneca Ltd	Amide derivatives
US5716972A (en)	1993-01-13	1998-02-10	Smithkline Beecham Corporation	Pyridyl substituted imidazoles
JP3264492B2 (ja)	1992-01-13	2002-03-11	スミスクライン・ビーチャム・コーポレイション	ピリジル置換イミダゾール
IL104369A0 (en)	1992-01-13	1993-05-13	Smithkline Beecham Corp	Novel compounds and compositions
US6008235A (en)	1992-01-13	1999-12-28	Smithkline Beecham Corporation	Pyridyl substituted imidazoles
US5916891A (en)	1992-01-13	1999-06-29	Smithkline Beecham Corporation	Pyrimidinyl imidazoles
US5656644A (en)	1994-07-20	1997-08-12	Smithkline Beecham Corporation	Pyridyl imidazoles
GB9303993D0 (en)	1993-02-26	1993-04-14	Fujisawa Pharmaceutical Co	New heterocyclic derivatives
US5593991A (en)	1993-07-16	1997-01-14	Adams; Jerry L.	Imidazole compounds, use and process of making
IL110296A (en)	1993-07-16	1999-12-31	Smithkline Beecham Corp	Imidazole compounds process for their preparation and pharmaceutical compositions containing them
US5670527A (en)	1993-07-16	1997-09-23	Smithkline Beecham Corporation	Pyridyl imidazole compounds and compositions
US5593992A (en)	1993-07-16	1997-01-14	Smithkline Beecham Corporation	Compounds
AU7629594A (en)	1993-07-21	1995-02-20	Smithkline Beecham Corporation	Imidazoles for treating cytokine mediated disease
US5869043A (en)	1993-09-17	1999-02-09	Smithkline Beecham Corporation	Drug binding protein
US5871934A (en)	1993-09-17	1999-02-16	Smithkline Beecham Corporation	Screening methods using cytokine suppressive anti-inflammatory drug (CSAID) binding proteins
US5783664A (en)	1993-09-17	1998-07-21	Smithkline Beecham Corporation	Cytokine suppressive anit-inflammatory drug binding proteins
AU693475B2 (en)	1993-10-01	1998-07-02	Novartis Ag	Pyrimidineamine derivatives and processes for the preparation thereof
PT672042E (pt)	1993-10-01	2006-08-31	Novartis Ag	Derivados de pirimidinoamina farmacologicamente activos e processos para a sua preparacao
US5543520A (en)	1993-10-01	1996-08-06	Ciba-Geigy Corporation	Pyrimidine derivatives
DE69429078T2 (de)	1993-10-01	2002-07-11	Novartis Ag, Basel	Pharmacologisch wirksame pyridinderivate und verfahren zu deren herstellung
EP1306377A3 (de)	1993-11-08	2003-05-07	Smithkline Beecham Corporation	Pyridyl-Oxazole und ihre Verwendung als Cytokine-Inhibitoren
US5559137A (en)	1994-05-16	1996-09-24	Smithkline Beecham Corp.	Compounds
US5545669A (en)	1994-06-02	1996-08-13	Adams; Jerry L.	Anti-inflammatory compounds
PL321292A1 (en)	1995-01-12	1997-11-24	Smithkline Beecham Corp	Novel xchemical compounds
IL118544A (en)	1995-06-07	2001-08-08	Smithkline Beecham Corp	History of imidazole, the process for their preparation and the pharmaceutical preparations containing them
US5739143A (en)	1995-06-07	1998-04-14	Smithkline Beecham Corporation	Imidazole compounds and compositions
CA2228050A1 (en)	1995-08-10	1997-02-20	Harold G. Selnick	2,5-substituted aryl pyrroles, compositions containing such compounds and methods of use
JP3294616B2 (ja)	1995-08-10	2002-06-24	メルクエンドカンパニーインコーポレーテッド	２−置換アリールピロール、このような化合物を含む組成物及び使用方法
IL123950A (en)	1995-10-06	2001-04-30	Merck & Co Inc	Substituted imidazoles having anti-cancer and cytokine inhibitory activity and pharmaceutical compositions containing them
WO1997016442A1 (en)	1995-10-31	1997-05-09	Merck & Co., Inc.	Substituted pyridyl pyrroles, compositions containing such compounds and methods of use
AU7482396A (en)	1995-10-31	1997-05-22	Merck & Co., Inc.	Substituted aryl pyrroles, compositions containing such compounds and methods of use
AU7529096A (en)	1995-10-31	1997-05-22	Merck & Co., Inc.	Substituted aryl pyrroles, compositions containing such compounds and methods of use
ZA9610687B (en)	1995-12-22	1997-09-29	Smithkline Beecham Corp	Novel synthesis.
ZA97175B (en)	1996-01-11	1997-11-04	Smithkline Beecham Corp	Novel substituted imidazole compounds.
US5756499A (en)	1996-01-11	1998-05-26	Smithkline Beecham Corporation	Substituted imidazole compounds
AP9700912A0 (en)	1996-01-11	1997-01-31	Smithkline Beecham Corp	Novel cycloalkyl substituted imidazoles
EP0883402A4 (de)	1996-01-11	1999-08-11	Smithkline Beecham Corp	Neue cycloalkyl substituierte imidazole
EP1005343A4 (de)	1996-03-08	2000-06-07	Smithkline Beecham Corp	Verwendung von csaids als inhibitoren der angiogenese
US6096748A (en)	1996-03-13	2000-08-01	Smithkline Beecham Corporation	Pyrimidine compounds useful in treating cytokine mediated diseases
WO1997035855A1 (en)	1996-03-25	1997-10-02	Smithkline Beecham Corporation	Novel treatment for cns injuries
WO1997035856A1 (en)	1996-03-25	1997-10-02	Smithkline Beecham Corporation	Novel treatment for cns injuries
JP2000504023A (ja)	1996-04-03	2000-04-04	メルクエンドカンパニーインコーポレーテッド	癌治療方法
AU708883B2 (en)	1996-06-10	1999-08-12	Merck & Co., Inc.	Substituted imidazoles having cytokine inhibitory activity
SI0912518T1 (en)	1996-07-18	2003-12-31	Merck Frosst Canada & Co.	Substituted pyridines as selective cyclooxygenase-2 inhibitors
WO1998006715A1 (en)	1996-08-09	1998-02-19	Smithkline Beecham Corporation	Novel piperazine containing compounds
WO1998007425A1 (en)	1996-08-21	1998-02-26	Smithkline Beecham Corporation	Imidazole compounds, compositions and use
AU5147598A (en)	1996-10-17	1998-05-11	Smithkline Beecham Corporation	Methods for reversibly inhibiting myelopoiesis in mammalian tissue
HUP9903330A2 (hu)	1996-11-19	2000-03-28	Amgen Inc.	Gyulladásgátló hatású, aril- és heteroaril csoporttal szubsztituált kondenzált pirrolszármazékok, valamint ezeket tartalmazó gyógyászati készítmények
CA2271893A1 (en)	1996-11-20	1998-05-28	Linda L. Chang	Triaryl substituted imidazoles as glucagon antagonists
CA2274093C (en)	1996-12-05	2006-11-07	Amgen Inc.	Substituted pyrimidinone and pyridinone compounds and their use
ZA9711092B (en)	1996-12-11	1999-07-22	Smithkline Beecham Corp	Novel compounds.
US6147080A (en)	1996-12-18	2000-11-14	Vertex Pharmaceuticals Incorporated	Inhibitors of p38
US5929076A (en)	1997-01-10	1999-07-27	Smithkline Beecham Corporation	Cycloalkyl substituted imidazoles
HRP980143A2 (en)	1997-04-09	1999-02-28	Soo Sung Ko	4,4-disubstituted-3,4-dihydro-2 (1h)-quinazolinones useful as hiv reverse transcriptase inhibitors
HUP0002842A3 (en)	1997-04-24	2002-01-28	Ortho Mcneil Pharm Inc	Substituted imidazoles, process for producing them, pharmaceutical compositions containing them, their use and their intermediates
MA26487A1 (fr)	1997-04-29	2004-12-20	Smithkline Beecham Corp	Heterocyclecetohydrazides inhibiteurs de proteases, procede pour leur preparation et compositions pharmaceutiques les contenant .
US6514977B1 (en)	1997-05-22	2003-02-04	G.D. Searle & Company	Substituted pyrazoles as p38 kinase inhibitors
US5932576A (en)	1997-05-22	1999-08-03	G. D. Searle & Company	3(5)-heteroaryl substituted pyrazoles as p38 kinase inhibitors
US6087381A (en)	1997-05-22	2000-07-11	G. D. Searle & Company	Pyrazole derivatives as p38 kinase inhibitors
NZ501112A (en)	1997-05-22	2002-10-25	G	Substituted pyrazoles as p38 kinase inhibitors
EP1019040B1 (de)	1997-05-23	2004-09-29	Bayer Corporation	Arylharnstoffderivate zur behandlung von inflammatorischen oder immunomodulatorischen erkrankungen
AU742293B2 (en)	1997-06-12	2001-12-20	Aventis Pharma Limited	Imidazolyl-cyclic acetals
US20020156104A1 (en)	1997-06-13	2002-10-24	Jerry L. Adams	Novel pyrazole and pyrazoline substituted compounds
JP2002505690A (ja)	1997-06-19	2002-02-19	スミスクライン・ビーチャム・コーポレイション	新規なアリールオキシピリミジン置換イミダゾール化合物
US6093742A (en)	1997-06-27	2000-07-25	Vertex Pharmaceuticals, Inc.	Inhibitors of p38
GB9713726D0 (en)	1997-06-30	1997-09-03	Ciba Geigy Ag	Organic compounds
AU8757098A (en)	1997-06-30	1999-02-10	Ortho-Mcneil Pharmaceutical, Inc.	2-substituted imidazoles useful in the treatment of inflammatory diseases
US6251914B1 (en)	1997-07-02	2001-06-26	Smithkline Beecham Corporation	Cycloalkyl substituted imidazoles
TW517055B (en)	1997-07-02	2003-01-11	Smithkline Beecham Corp	Novel substituted imidazole compounds
AR016294A1 (es)	1997-07-02	2001-07-04	Smithkline Beecham Corp	Compuesto de imidazol sustituido, composicion farmaceutica que la contiene, su uso en la fabricacion de un medicamento y procedimiento para supreparacion
US6362193B1 (en)	1997-10-08	2002-03-26	Smithkline Beecham Corporation	Cycloalkenyl substituted compounds
EP1021173A1 (de)	1997-10-10	2000-07-26	Imperial College Innovations Limited	Verwendung von cytokin-unterdrückenden verbindungen (csaid) zur behandlung von gebärmutterkontraktionen
JP2001526230A (ja)	1997-12-19	2001-12-18	スミスクライン・ビーチャム・コーポレイション	ヘテロアリール置換イミダゾール化合物、その医薬組成物および使用
JP2002515891A (ja)	1997-12-19	2002-05-28	スミスクライン・ビーチャム・コーポレイション	新規なピペリジン含有化合物
IL136768A0 (en)	1997-12-22	2001-06-14	Bayer Ag	INHIBITION OF p38 KINASE ACTIVITY USING ARYL AND HETEROARYL SUBSTITUTED HETEROCYCLIC UREAS
US6162613A (en)	1998-02-18	2000-12-19	Vertex Pharmaceuticals, Inc.	Methods for designing inhibitors of serine/threonine-kinases and tyrosine kinases
JP2002513562A (ja)	1998-05-04	2002-05-14	バーテックスファーマシューティカルズインコーポレイテッド	結晶化可能なｊｎｋ複合体
PL344004A1 (en)	1998-05-05	2001-09-10	Hoffmann La Roche	Pyrazole derivatives as p-38 map kinase inhibitors
GB9809869D0 (en)	1998-05-09	1998-07-08	Medical Res Council	Inhibition of protein kinases
MY132496A (en)	1998-05-11	2007-10-31	Vertex Pharma	Inhibitors of p38
WO1999058523A1 (en)	1998-05-14	1999-11-18	G.D. Searle & Co.	1,5-DIARYL SUBSTITUTED PYRAZOLES AS p38 KINASE INHIBITORS
IL139710A (en)	1998-05-15	2005-07-25	Astazeneca Ab	Benzamide derivatives for the treatment of diseases mediated by cytokines
US6579872B1 (en)	1998-05-15	2003-06-17	Astrazeneca Ab	Bezamide derivatives for the treatment of diseases mediated by cytokines
BR9910621A (pt)	1998-05-22	2001-01-30	Smithkline Beecham Corp	Novos compostos de imidazol 2-alquil substituìdos
EP1080078B1 (de)	1998-05-22	2006-02-01	Scios Inc.	Heterozyclische derivate für die behandlung von herzversagen und andere erkrankungen
CA2333157A1 (en)	1998-05-26	1999-12-02	Smithkline Beecham Corporation	Novel substituted imidazole compounds
AU4429799A (en) *	1998-06-12	1999-12-30	Vertex Pharmaceuticals Incorporated	Inhibitors of p38
AU4395399A (en)	1998-07-02	2000-01-24	Sankyo Company Limited	Five-membered heteroaryl compounds
US6207687B1 (en)	1998-07-31	2001-03-27	Merck & Co., Inc.	Substituted imidazoles having cytokine inhibitory activity
BR9912729A (pt)	1998-08-04	2001-05-02	Astrazeneca Ab	Derivado de amida, processo para prepará-lo, e, uso do mesmo
ES2221426T3 (es)	1998-08-20	2004-12-16	Smithkline Beecham Corporation	Nuevos compuestos de triazol sustituidos.
US6184226B1 (en)	1998-08-28	2001-02-06	Scios Inc.	Quinazoline derivatives as inhibitors of P-38 α
CA2342251A1 (en)	1998-08-28	2000-03-09	Scios Inc.	Use of piperidines and/or piperazines as inhibitors of p38-alpha kinase
AU762245B2 (en)	1998-09-18	2003-06-19	Vertex Pharmaceuticals Incorporated	Inhibitors of p38
ATE254105T1 (de)	1998-09-25	2003-11-15	Astrazeneca Ab	Benzamid-derivate und ihre verwendung als cytokine inhibitoren
CN1158266C (zh)	1998-10-01	2004-07-21	阿斯特拉曾尼卡有限公司	化合物
FI982125A0 (fi)	1998-10-01	1998-10-01	Hk Ruokatalo Oyj	Terveyteen myönteisesti vaikuttava elintarvike
EP1261334A1 (de)	1998-10-20	2002-12-04	Omeros Corporation	Spüllösung enthaltend mapk hemmern und deren verwendung zur behandlung von schmerz und entzündung
PL347432A1 (en)	1998-10-23	2002-04-08	Hoffmann La Roche	Bicyclic nitrogen heterocycles
WO2000026209A1 (en)	1998-11-03	2000-05-11	Novartis Ag	Anti-inflammatory 4-phenyl-5-pyrimidinyl-imidazoles
US6548503B1 (en)	1998-11-04	2003-04-15	Smithkline Beecham Corporation	Pyridin-4-yl or pyrimidin-4-yl substituted pyrazines
EP1131318B1 (de)	1998-11-20	2004-03-24	G.D. Searle LLC	Verfahren zur herstellung 5-substituierter pyrazole unter verwendung von dithietane
US6350744B1 (en)	1998-11-20	2002-02-26	Merck & Co., Inc.	Compounds having cytokine inhibitory activity
EP1140916B1 (de)	1998-12-16	2002-11-13	Aventis Pharma Limited	Heteroaryl-zyklische acetale
KR100711538B1 (ko)	1998-12-25	2007-04-27	아스카 세이야쿠 가부시키가이샤	아미노피라졸 유도체
EP1140083A4 (de)	1999-01-08	2004-01-02	Smithkline Beecham Corp	Neue verbindungen
UA73492C2 (en)	1999-01-19	2005-08-15		Aromatic heterocyclic compounds as antiinflammatory agents
JP2000281588A (ja)	1999-03-30	2000-10-10	Sankyo Co Ltd	ガンの予防又は治療薬及びそのスクリーニング方法
CN1281604C (zh)	1999-06-03	2006-10-25	帝国脏器制药株式会社	取代吡唑化合物
WO2001000229A1 (en)	1999-06-24	2001-01-04	Pharmacia Corporation	Combination of tumors necrocis factor (tnf) antagonists and cox-2 inhibitors for the treatment of inflammation
KR20020032591A (ko)	1999-09-17	2002-05-03	스튜어트 알. 수터, 스티븐 베네티아너, 피터 존 기딩스	라이노바이러스 감염에서의 ｃｓａｉｄ의 용도
ES2230171T3 (es)	1999-11-23	2005-05-01	Smithkline Beecham Corporation	Compuestos 3,4-dihidro-(1h)quinazolin-2-ona como inhibidores de csbp/p38 quinasa.
JP2003514900A (ja)	1999-11-23	2003-04-22	スミスクライン・ビーチャム・コーポレイション	ＣＳＢＰ／ｐ３８キナーゼ阻害剤としての３，４−ジヒドロ−（１Ｈ）−キナゾリン−２−オン化合物
WO2001037837A1 (en)	1999-11-23	2001-05-31	Smithkline Beecham Corporation	3,4-DIHYDRO-(1H)-QUINAZOLIN-2-ONES AND THEIR USE AS CSBP/p38 KINASE INHIBITORS
DE60023025T2 (de)	1999-11-23	2006-07-13	Smithkline Beecham Corp.	3,4-dihydro-(1h)chinazolin-2-on-verbindungen als csbp/p39-kinase-inhibitoren
AR030053A1 (es)	2000-03-02	2003-08-13	Smithkline Beecham Corp	1h-pirimido [4,5-d] pirimidin-2-onas y sales, composiciones farmaceuticas, uso para la fabricacion de un medicamento y procedimiento para producirlas
NL1015713C2 (nl)	2000-07-14	2002-01-15	Doornes Transmissie Bv	Werkwijze voor het verwijderen van meerdere gestanste producten uit een werkzaam gebied van een stansinrichting met meerdere stempels.
US6406079B2 (en)	2000-07-14	2002-06-18	Kyoraku Co., Ltd.	Automobile bumper core
US6565880B2 (en)	2000-07-24	2003-05-20	Boehringer Ingelheim Pharmaceuticals, Inc.	Oral dosage formulations of 1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-urea
JP2004521892A (ja)	2000-12-20	2004-07-22	メルク　エンド　カムパニー　インコーポレーテッド	（ハロ−ベンゾカルボニル）複素環縮合フェニル系ｐ３８キナーゼ阻害剤

2000
- 2000-11-21 DE DE60023025T patent/DE60023025T2/de not_active Expired - Lifetime
- 2000-11-21 ES ES00980576T patent/ES2249309T3/es not_active Expired - Lifetime
- 2000-11-21 US US10/129,863 patent/US6982270B1/en not_active Expired - Fee Related
- 2000-11-21 AT AT00980576T patent/ATE305787T1/de not_active IP Right Cessation
- 2000-11-21 JP JP2001540076A patent/JP2003528043A/ja not_active Withdrawn
- 2000-11-21 AU AU17823/01A patent/AU1782301A/en not_active Abandoned
- 2000-11-21 WO PCT/US2000/031874 patent/WO2001038313A1/en not_active Ceased
- 2000-11-21 EP EP00980576A patent/EP1233950B1/de not_active Expired - Lifetime

Also Published As

Publication number	Publication date
EP1233950B1 (de)	2005-10-05
WO2001038313A1 (en)	2001-05-31
US6982270B1 (en)	2006-01-03
AU1782301A (en)	2001-06-04
DE60023025T2 (de)	2006-07-13
JP2003528043A (ja)	2003-09-24
ES2249309T3 (es)	2006-04-01
DE60023025D1 (de)	2006-02-16
EP1233950A4 (de)	2003-03-26
EP1233950A1 (de)	2002-08-28

Legal Events

Date	Code	Title	Description
2006-04-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
DE60023025D1 (de)	2006-02-16	3,4-dihydro-(1h)chinazolin-2-on-verbindungen als csbp/p39-kinase-inhibitoren
ATE296809T1 (de)	2005-06-15	3,4-dihydro-(1h)chinazolin-2-on-verbindungen als csbp/p38-kinase-inhibitoren
ATE270278T1 (de)	2004-07-15	Phthalazinone pde iii/iv hemmer
DE60315146D1 (de)	2007-09-06	Heteroarylsubstituierte biphenylderivate als inhibitoren von p38-kinase
DE60214703D1 (de)	2006-10-26	Thiazolverbindungen, die sich als inhibitoren von proteinkinasen eignen
ATE266399T1 (de)	2004-05-15	Neue substituierte triazolverbindungen
ATE228507T1 (de)	2002-12-15	Substituierte 6-phenylphenanthridine
DK1333833T3 (da)	2011-12-12	Ny trisubstitueret 8H-pyridol[2,3-d]pyrimidin-7-on-forbindelse til behandling af CSBP/RK/p38-kinnasemedierede sygdomme
AP2001002172A0 (en)	2001-06-30	Substituted pyrazoles as p38 kinase inhibitors
AP1246A (en)	2004-02-07	Substituted pyrazoles as p38 Kinase inhibitors.
DK0889886T5 (da)	2003-02-24	Hidtil ukendte, i 6-stilling substituerede phenanthridiner
EE200000033A (et)	2000-10-16	Uudsed tetrasoolderivaadid
ATE281439T1 (de)	2004-11-15	3,4-dihydro-(1h)chinazolin-2-on-verbindungen als csbp/p38-kinase-inhibitoren
IS7507A (is)	2004-10-15	Ný efnasambönd
DE60127131D1 (de)	2007-04-19	Tricyclische imidazopyridine
DE60036558D1 (de)	2007-11-08	Phthalazinon-derivate als pde 4 hemmer
DE60202669D1 (de)	2005-02-24	6-phenylbenzonaphthyidine
TW200503722A (en)	2005-02-01	Substituted 7-aza-quinazoline compounds
AP2002002417A0 (en)	2002-03-31	Pyrimidine-2,4,6-trione metalloproteinase inhibitors.
DK1104419T3 (da)	2002-09-23	N-substituerede azabicyloheptan-derivater, deres fremstilling og anvendelse
ATE388710T1 (de)	2008-03-15	Phthalazinderivate als phosphodiesterase-4-hemmer
MY141481A (en)	2010-04-30	Substituted pyrazoles as p38 kinase inhibitors